Unlike previously reported prognostic markers (e.g., troponin and N‐terminal pro‐B‐type natriuretic peptide) which cannot provide additional information on therapeutic targets, this study also systematically described the cardiovascular and metabolic activities of recurrent MACE‐related PO and ARO metabolites in a murine MI/R model. This evidence concerns the gene CYP19A1 and myocardial infarction.